Overview

Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis

Status:
Completed
Trial end date:
1994-09-01
Target enrollment:
Participant gender:
Summary
To determine whether deferoxamine prevented the complications of transfusional iron overload.
Phase:
Phase 2
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Deferoxamine